Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 2008 Jun 2;52(8):2977–2979. doi: 10.1128/AAC.00175-08

VIM-15 and VIM-16, Two New VIM-2-Like Metallo-β-Lactamases in Pseudomonas aeruginosa Isolates from Bulgaria and Germany

Ines Schneider 1, Emma Keuleyan 2, Rudolf Rasshofer 3, Rumyana Markovska 4, Anne Marie Queenan 5, Adolf Bauernfeind 1,*
PMCID: PMC2493107  PMID: 18519714

Abstract

Two Pseudomonas aeruginosa urine isolates from Bulgaria and Germany produced two new VIM-2 variants. VIM-15 had one amino acid substitution (Tyr218Phe) which caused a significant increase in hydrolytic efficiency. The substitution Ser54Leu, characterizing VIM-16, showed no influence on enzyme activity. Both genes were part of class I integrons located in the chromosome.


VIM-type β-lactamases are commonly acquired metallo-β-lactamases (MBLs) mostly found in Pseudomonas aeruginosa (11). They contribute significantly to the resistance of nonfermenting gram-negative organisms to carbapenems. Furthermore, as all blaVIMs are part of integrons, their acquisition is often linked with resistance to other compounds, e.g., aminoglycosides.

We analyzed the MBLs of two P. aeruginosa strains that were isolated in Bulgaria and Germany.

(Part of this work was presented at the 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, 2007 [10].)

P. aeruginosa 166301 was isolated in April 2005 at the Medizinisches Versorgungszentrum, Munich, Germany, from the urine of a 76-year-old male patient. P. aeruginosa 9551 was recovered in March 2006 at the Medical Institute, Ministry of the Interior, Sofia, Bulgaria, from the urine of a 49-year-old male patient treated at the nephrology ambulatory clinic.

MICs, determined by the agar dilution technique following Clinical and Laboratory Standards Institute (formerly NCCLS) guidelines (6), are shown in Table 1. Both P. aeruginosa strains were resistant to carbapenems, suggesting the presence of carbapenemases. The results of a Hodge test and a double-disk synergy test with EDTA, carried out as described previously (5), demonstrated the production of carbapenem-hydrolyzing enzymes susceptible to EDTA inhibition, thereby confirming the presence of MBLs.

TABLE 1.

Antibiotic susceptibilities of wild-type and transformant strains

Antibiotics MIC (μg/ml) for:
P. aeruginosa
E. coli DH5α
9551 (VIM-15) 166301 (VIM-16) pBC-VIM-15 pBC-VIM-16 pBC-VIM-2 Host strain
Amoxicillin 512 >512 256 256 256 4
Piperacillin-tazobactama 128 128 8 8 4 1
Ceftazidime 64 64 0.5 0.5 1 0.13
Cefotaxime >256 >256 4 2 1 0.03
Cefepime 32 32 0.03 0.03 0.03 0.016
Aztreonam 16 32 0.016 0.016 0.016 0.016
Meropenem 128 >128 0.03 0.03 0.03 0.016
Imipenem >128 >128 0.5 0.25 0.25 0.25
Gentamicin 0.5 >128 0.13 0.13 0.13 0.13
Tobramycin 8 >128 0.25 0.25 0.25 0.25
a

Tazobactam was used at a fixed concentration of 4 μg/ml.

A PCR with blaVIM-specific oligonucleotides (VIM-F, 5′-TTGGTCGCATATCGCAAC-3′, and VIM-R, 5′-CGCAGCACCRGGATAGAA-3′) was positive. We used combinations of VIM-F and VIM-R with oligonucleotides binding to conserved regions of class I integrons (qacEΔ1, 5′-GCCAACTATTGCGATAAC-3′, and IntIa-attI, 5′-TCTATGCCTCGGGCATCC-3′) to sequence the whole gene and its environment. The sequences revealed close homology to blaVIM-2, although one nucleotide substitution causing an amino acid to differ from that in VIM-2 was found for both strains. The nucleotide substitution A584T leading to a tyrosine 218 phenylalanine substitution characterized the VIM enzyme of P. aeruginosa 9551 (MBL numbering according to Garau et al. [2]). At that position, all VIM-type MBLs described so far have a tyrosine, except for VIM-7, which also shows a phenylalanine but shares only 74% amino acid identity with VIM-2. The blaVIM of P. aeruginosa 166301 had one nucleotide substitution (C164T), causing a serine 54 leucine substitution. At that position, all other VIM variants carry a serine. These new VIM-type MBLs were named VIM-15 (P. aeruginosa 9551) and VIM-16 (P. aeruginosa 166301).

To explore whether the amino acid substitutions influence hydrolytic activity, we cloned the blaVIM genes of P. aeruginosa strain 9551, strain 166301, and the VIM-2-producing reference strain P. aeruginosa 98/10/U1315 in an isogenic background. Cloning was performed as described previously using the vector pBC and Escherichia coli DH5α (9). Primers VIM-2-EcoRI-V (5′-AGGAATTCCTAGTGCCGCACTCACC-3′) and VIM-2-BamHI-R (5′-CAGGATCCTTCATGTTATGCCG-3′) were used to amplify the gene, including 27 bp of the upstream and 18 bp of the downstream region. The expression of the blaVIM genes in the transformants led to significant increases in the MICs for amoxicillin (64-fold) and cefotaxime (32- to 128-fold), and to moderate increases in the MICs for piperacillin-tazobactam and ceftazidime (4- to 8-fold) (Table 1). The MICs of cefepime (2-fold increase), meropenem (2-fold increase), imipenem (1- to 2-fold increase), and aztreonam were not or only slightly affected. The absence of the original promoter, which was removed during cloning, caused MICs for ceftazidime that were lower than values found in the literature (7). Interestingly, the production of VIM-15 caused slightly higher MICs for cefotaxime and imipenem than the production of VIM-2 or VIM-16. Increased activity of VIM-15 in comparison to the activity of VIM-2 and VIM-16 against cefotaxime, meropenem, and imipenem could be seen by the results of a Hodge test using crude strain homogenates (data not shown).

The purification of β-lactamases from transformants producing VIM-15 and VIM-16 and the determination of kinetic parameters were carried out as described previously (8). Overnight cultures were centrifuged, washed with phosphate buffer, and subjected to five freeze-thaw cycles. Following centrifugation, supernatants were filtered and passed through a Superdex 100 gel filtration column. Active fractions were further purified by using HiTrap SP cation and Q anion exchange columns. The data for VIM-2, previously obtained using the same procedure, were taken from Queenan et al. (8).

Both VIM-15 and VIM-16 showed a higher turnover rate (kcat) for cefotaxime than for ceftazidime and cefepime, resulting in higher hydrolytic efficiencies (kcat/Km) for cefotaxime (Table 2). All three enzymes hydrolyzed imipenem faster than meropenem and, as is typical for MBLs, aztreonam was hydrolyzed only very slowly.

TABLE 2.

Kinetic parameters of VIM-15, VIM-16, and VIM-2a

Substrate VIM-15
VIM-16
VIM-2
kcat (s−1) Relativebkcat Km (μM) kcat/Km (s−1 μM−1) Relativebkcat/Km kcat (s−1) Relativebkcat Km (μM) kcat/Km (s−1 μM−1) Relativebkcat/Km kcat (s−1) Relativebkcat Km (μM) kcat/Km (s−1 μM−1) Relativebkcat/Km
Cephaloridine 190 ± 4 100 83 ± 2 2.3 100 89 ± 2 100 1400 ± 53 0.064 100 120 ± 5 100 1400 ± 6 0.086 100
Benzylpenicillin 240 ± 3 130 25 ± 0.5 9.6 420 230 ± 24 260 450 ± 8 0.51 800 73 ± 0.4 61 150 ± 1 0.49 570
Cefepime 9.5 ± 0.1 5.0 130 ± 2 0.076 3.3 0.31 ± 0.03 0.35 210 ± 1 0.0015 2.3 0.38 ± 0.02 0.32 110 ± 6 0.0035 4.1
Ceftazidime 1.0 ± 0.04 0.53 37 ± 2 0.027 1.2 0.22 ± 0.00 0.25 150 ± 2 0.0014 2.2 0.23 ± 0.01 0.19 150 ± 6 0.0015 1.7
Cefotaxime 90 ± 7 47 13 ± 1 6.9 300 81 ± 0.2 91 240 ± 9 0.34 530 NT NT NT NT NT
Imipenem 61 ± 2 32 7.3 ± 0.5 8.4 370 45 ± 2 51 89 ± 2 0.51 800 20 ± 0.3 17 60 ± 2 0.33 380
Meropenem 6.5 ± 0.05 3.4 3.4 ± 0.5 1.9 83 8.4 ± 0.3 9.4 120 ± 5 0.070 110 2.1 ± 0.1 1.8 40 ± 2 0.053 62
Aztreonamc ≤0.031 ≤0.016 ND ND ND ≤0.11 ≤0.12 ND ND ND NT NT NT NT NT
a

NT, not tested; ND, not determined as hydrolysis was too slow to determine Km.

b

The cephaloridine value was taken as 100%.

c

Hydrolysis of aztreonam was very slow; Vmax was estimated as 2 times the maximum hydrolysis rate observed.

VIM-16 presented kcat and Km values very similar to those for VIM-2, resulting in similar hydrolytic efficiencies. The amino acid substitution from serine to leucine at position 54 is located on the second β-strand of the enzyme (3). Although this is a nonconservative change, because of its remote position in relation to the active site, no influence on the hydrolytic activity is expected.

VIM-15 showed hydrolytic efficiencies about 1 order of magnitude higher than those of VIM-2 and VIM-16 for all substrates tested. This is caused by lower Km values for cephaloridine, cefotaxime, imipenem, and meropenem, indicating a stronger affinity of VIM-15 for those substrates. In contrast, the increased activity for cefepime was caused by an elevated turnover rate. The higher efficiencies for ceftazidime and benzylpenicillin were a result of both increased turnover rate and decreased Km values. The change from tyrosine to phenylalanine at position 218 is located on β-strand 11 (3) and has a conservative character. However, this substitution is near the cysteine zinc binding site (Cys221) and apparently affected the binding properties or catalytic activity of VIM-15.

Both blaVIM-15 and blaVIM-16 were part of class I integrons. The integron of P. aeruginosa 9551 harbored the blaVIM-15 cassette only. This structure is identical to that of the VIM-2-producing P. aeruginosa COL-1 isolated in 1996 in France (7). The blaVIM-16 cassette of P. aeruginosa 166301 was flanked by two aac(6′)-Ib′ cassettes coding for an aminoglycoside acetyltransferase. This structure is identical to that of the VIM-2-producing P. aeruginosa B63230 isolated in 2003 in Germany, except that the integron of P. aeruginosa B63230 additionally harbored cmlA and ant(3")-Ib cassettes (4). For P. aeruginosa 9551, the absence of cassettes coding for aminoglycoside-modifying enzymes is in accordance with the susceptibility to aminoglycosides, while P. aeruginosa 166301, harboring two genes of an aminoglycoside acetyltransferase, was highly resistant to aminoglycosides (Table 1).

To test whether the blaVIM-containing integrons reside on plasmids, we tried transferring them by conjugation to E. coli C600 R (1) and by electroporation to E. coli DH5α. Both attempts failed. The blaVIM localization was further analyzed by performing Southern blotting of plasmid preparations (Qiagen plasmid midi kit; Qiagen, Hilden, Germany) followed by hybridization with probes amplified from blaVIM (VIM-F and VIM-2-BamHI-R) and 16S rRNA (616V, 5′-AGAGTTTGATCMKGGCTCAG-3′, and 610R, 5′-CAGGATCCTTCATGTTATGCCG-3′) using a Gene Images AlkPhos direct labeling and detection system (GE Healthcare, Little Chalfont, United Kingdom). In addition, we treated plasmid DNA preparations with Plasmid-safe (Epicenter Biotechnologies, Madison, WI), a DNase which selectively digests linear DNA, but not circular DNA. For both P. aeruginosa strains, a DNA band which was recognized by the VIM probe as well as by the 16S rRNA probe and which was affected by treatment with Plasmid-safe was found. Assuming that those bands are chromosomal DNA, the blaVIM genes appear to be chromosomally located.

In conclusion, the isolation of two new VIM-type MBLs in Bulgaria and Germany highlights the ongoing spread and evolution of this group of β-lactamases. VIM-type MBLs have already been described in Germany (4, 12), although no report on VIM MBLs in Bulgaria was found. While the Ser54Leu substitution has no influence on hydrolytic activity, the amino acid change from tyrosine to phenylalanine at position 218 enhances enzymatic activity.

Nucleotide sequence accession numbers.

The nucleotide sequences of blaVIM-15 and blaVIM-16 have been deposited in the GenBank database under accession numbers EU419745 and EU419746.

Acknowledgments

We thank Wenchi Shang, Johnson & Johnson Pharmaceutical Research and Development, Raritan, NJ, for purification of the VIM β-lactamases and Yunsop Chong and Kyungwon Lee, Yonsei University College of Medicine, Seoul, Korea, for providing us with the VIM-2 reference strain P. aeruginosa 98/10/U1315.

Footnotes

Published ahead of print on 2 June 2008.

REFERENCES

  • 1.Bauernfeind, A., S. Wagner, R. Jungwirth, I. Schneider, and D. Meyer. 1997. A novel class C β-lactamase (FOX-2) in Escherichia coli conferring resistance to cephamycins. Antimicrob. Agents Chemother. 41:2041-2046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Garau, G., I. García-Sáez, C. Bebrone, C. Anne, P. Mercuri, M. Galleni, J. M. Frère, and O. Dideberg. 2004. Update of the standard numbering scheme for class B β-lactamases. Antimicrob. Agents Chemother. 48:2347-2349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Garcia-Saez, I., J. D. Docquier, G. M. Rossolini, and O. Dideberg. 2008. The three-dimensional structure of VIM-2, a Zn-β-lactamase from Pseudomonas aeruginosa in its reduced and oxidised form. J. Mol. Biol. 375:604-611. [DOI] [PubMed] [Google Scholar]
  • 4.Henrichfreise, B., I. Wiegand, K. J. Sherwood, and B. Wiedemann. 2005. Detection of VIM-2 metallo-β-lactamase in Pseudomonas aeruginosa from Germany. Antimicrob. Agents Chemother. 49:1668-1669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Lee, K., Y. Chong, H. B. Shin, Y. A. Kim, D. Yong, and J. H. Yum. 2001. Modified Hodge and EDTA-disk synergy tests to screen metallo-β-lactamase-producing strains of Pseudomonas and Acinetobacter species. Clin. Microbiol. Infect. 7:88-91. [DOI] [PubMed] [Google Scholar]
  • 6.National Center for Clinical and Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing, 12th informational supplement. M100-S12. National Center for Clinical and Laboratory Standards, Wayne, PA.
  • 7.Poirel, L., T. Naas, D. Nicolas, L. Collet, S. Bellais, J. D. Cavallo, and P. Nordmann. 2000. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob. Agents Chemother. 44:891-897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Queenan, A. M., W. Shang, M. Kania, M. G. P. Page, and K. Bush. 2007. Interactions of ceftobiprole with β-lactamases from molecular classes A to D. Antimicrob. Agents Chemother. 51:3089-3095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Schneider, I., R. Markovska, E. Keuleyan, M. Sredkova, K. Rachkova, I. Mitov, and A. Bauernfeind. 2007. Dissemination and persistence of a plasmid-mediated TEM-3-like β-lactamase, TEM-139, among Enterobacteriaceae in Bulgaria. Int. J. Antimicrob. Agents 29:710-714. [DOI] [PubMed] [Google Scholar]
  • 10.Schneider, I., E. Keuleyan, R. Rasshofer, and A. Bauernfeind. 2007. New VIM-2-like metallo-beta-lactamases in P. aeruginosa from Germany and Bulgaria. Clin. Microbiol. Infect. 13(Suppl. 1):S107. [Google Scholar]
  • 11.Walsh, T. R., M. A. Toleman, L. Poirel, and P. Nordmann. 2005. Metallo-β-lactamases: the quiet before the storm? Clin. Microbiol. Rev. 18:306-325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Weile, J., H. Rahmig, S. Gfröer, K. Schroeppel, C. Knabbe, and M. Susa. 2007. First detection of a VIM-1 metallo-β-lactamase in a carbapenem-resistant Citrobacter freundii clinical isolate in an acute hospital in Germany. Scand. J. Infect. Dis. 39:264-266. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES